EL7.AI
StocksMedium•10 November 2026•
4 min read

Alenura Outperforms Three Comparators in Phase 2 Trial for Bladder Pain

Key Facts

1Alenura was statistically superior to placebo, alkalinized lidocaine and heparin on the SPID-12 endpoint, with p-values below 0.01.
2The Phase 2 study included 153 adults in the United States in a randomized, double-blind design with four groups.
3Pain-relief assessments at 24 hours also favored Alenura.
4The companies estimate that 6 million people or more in the United States have symptoms consistent with the condition.
5Preparations are underway for a U.S. New Drug Application under 505(b)(2), subject to completing clinical and regulatory requirements.

Hyloris and Vaneltix announced positive efficacy results on November 8, 2026, from the Phase 2 VNX001-111 study of Alenura, which is intended to relieve acute bladder pain flares associated with interstitial cystitis and bladder pain syndrome. Hyloris said the study met its primary endpoint, the sum of changes in bladder pain intensity over 12 hours, and showed that Alenura was statistically superior to placebo and to alkalinized lidocaine and heparin individually. All reported p-values were below 0.01. The comparison with the two components is significant because the formulation combines two treatments, each used for a different purpose in the bladder. The companies said the results support continued development of the drug and preparations for a U.S. New Drug Application under 505(b)(2), with clinical and regulatory requirements still to be met before any filing.

The trial included 153 adults with interstitial cystitis or bladder pain syndrome who had moderate to severe acute pain, at sites in the United States. The study was randomized, double-blind and placebo-controlled, with participants assigned to 4 groups. Each participant received a single intravesical instillation of Alenura, placebo, alkalinized lidocaine or heparin alone. This design compared the combination with placebo and with each therapeutic component individually within the same trial. The SPID-12 measure combined changes in pain intensity across the specified measurement window, rather than relying on a single pain reading.

Supportive efficacy signals extended beyond the primary endpoint: the company said pain-relief assessments at 24 hours also favored Alenura. It added that patient-reported symptom-improvement assessments provided further support for the results. The release did not report an effect size at 24 hours or quantitative detail for the symptom-improvement measure. The reported primary result therefore focused on statistical superiority over 12 hours, while the later measurements were supportive results. This places the two measurement windows in context: a defined primary endpoint at 12 hours and later signals at 24 hours.

Alenura is a ready-to-use solution administered by intravesical instillation and combines alkalinized lidocaine and heparin. Lidocaine, a local anesthetic, is intended to provide rapid pain relief, while heparin is intended to support the bladder's protective lining. The combination's superiority over each component individually reflects the question the study tested about using them together, alongside comparison with placebo. The announced results remain Phase 2 efficacy results, and further clinical and regulatory steps are still required before an approval application. The intended use is for acute flares within a chronic condition whose symptoms can fluctuate.

Hyloris describes interstitial cystitis and bladder pain syndrome as a chronic condition involving recurrent bladder or pelvic pain or discomfort, which may be accompanied by an urgent and frequent need to urinate. Acute pain flares can last from several hours to several days, and there is no cure for the condition, according to the release. The companies estimate that 6 million people or more in the United States have symptoms consistent with the condition. The U.S. National Institute of Diabetes and Digestive and Kidney Diseases estimates that the number of people with interstitial cystitis in the United States may range from 4 million to 12 million, noting that the condition can be confused with other diseases. The institute lists intravesical drug instillation among a range of management options, alongside bladder training, physical therapy, medicines and bladder distension.

On the treatment landscape, Hyloris said no treatment has specific U.S. Food and Drug Administration approval for acute bladder pain associated with interstitial cystitis. The FDA database shows prior approval of pentosan polysulfate sodium, known as Elmiron, to relieve bladder pain or discomfort associated with interstitial cystitis; marketing approval was granted on September 26, 1996. The registered indication is for relief of pain or discomfort associated with the disease, while the companies frame Alenura's goal around acute pain flares. The companies said additional development activities are underway to support preparations for a 505(b)(2) application to the FDA. Vaneltix Chief Executive Dan Vickery added that the companies are seeking to generate the remaining evidence needed for an approval application in the United States and other markets; the release did not specify a filing date.